These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 410692)

  • 21. [Single intravenous glibenclamide-glucose loading as a prediction test (author's transl)].
    Pfeiffer EF; Raptis S; Schröder KE
    Dtsch Med Wochenschr; 1974 Jun; 99(24):1281-94. PubMed ID: 4210532
    [No Abstract]   [Full Text] [Related]  

  • 22. Influence of verapamil on human glucose tolerance.
    Röjdmark S; Andersson DE
    Am J Cardiol; 1986 Feb; 57(7):39D-43D. PubMed ID: 3082174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Behaviour of glibenclamide on repeated administration to diabetic patients.
    Balant L; Zahnd GR; Weber F; Fabre J
    Eur J Clin Pharmacol; 1977; 11(1):19-25. PubMed ID: 401739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum insulin in obesity and diabetes mellitus.
    Boshell BR; Chandalia HB; Kreisberg RA; Roddam RF
    Am J Clin Nutr; 1968 Dec; 21(12):1419-28. PubMed ID: 5724820
    [No Abstract]   [Full Text] [Related]  

  • 25. Topical application of the hypoglycemic agent glibenclamide and changes in blood glucose, plasma insulin (IRI) levels and plasma concentration of glibenclamide in normal rats.
    Yamamoto T; Katakabe K; Akiyoshi K; Kan K; Asano T; Okumura M
    Diabetes Res Clin Pract; 1990 Jan; 8(1):19-22. PubMed ID: 2105197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucose, FFA, IRI and GH response to I.V. glibenclamide.
    Rastogi GK; Dash RJ; Sinha MK
    Horm Metab Res; 1973 Jul; 5(4):303. PubMed ID: 4199903
    [No Abstract]   [Full Text] [Related]  

  • 27. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
    Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
    J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mechanism of action of combined administration of glibenclamide and insulin in type II diabetics with secondary failure of oral treatment].
    Schmidt FH; Klujko J; Kühnle HF; Reiter J
    Klin Wochenschr; 1986 Oct; 64(20):1021-3. PubMed ID: 3097384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Steady state plasma insulin response to continuous glucose infusion in normal and diabetic subjects.
    Reaven GM; Farquhar JW
    Diabetes; 1969 May; 18(5):273-9. PubMed ID: 5795851
    [No Abstract]   [Full Text] [Related]  

  • 31. Insulin response in patients receiving concentrated infusions of glucose and casein hydrolysate for complete parenteral nutrition.
    Sanderson I; Deitel M
    Ann Surg; 1974 Apr; 179(4):387-94. PubMed ID: 4205794
    [No Abstract]   [Full Text] [Related]  

  • 32. Intravenous glucose tolerance and early insulin response. Studies on a random sample of women aged 50 and patients with diabetes mellitus.
    Blohmé G
    Acta Med Scand Suppl; 1974; 566():1-121. PubMed ID: 4533586
    [No Abstract]   [Full Text] [Related]  

  • 33. [Increase of the betazytotropic effect of intravenous arginine administration through glibenclamide in subjects with healthy metabolism and in patients with latent and manifest diabetes].
    Sorge F; Neuhaus GA
    Med Welt; 1975 Oct; 26(42):1922-7. PubMed ID: 810637
    [No Abstract]   [Full Text] [Related]  

  • 34. Does verapamil influence glucose-induced insulin release in man?
    Röjdmark S; Andersson DE; Hed R; Nordlund A; Sundblad L; Wiechel KL
    Acta Med Scand; 1981; 210(6):501-5. PubMed ID: 7036659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration in diabetic subjects.
    Haupt E; Köberich W; Beyer J; Schöffling K
    Diabetologia; 1971 Dec; 7(6):449-54. PubMed ID: 5004178
    [No Abstract]   [Full Text] [Related]  

  • 36. Extrapancreatic insulin effect of glibenclamide.
    Mulder H; Schopman W; van der Lely AJ
    Eur J Clin Pharmacol; 1991; 40(4):379-81. PubMed ID: 1904820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
    Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on the dynamics and mechanism of glibenclamide-induced insulin secretion.
    Basabe JC; Farina JM; Chieri RA
    Horm Metab Res; 1976 Nov; 8(6):413-9. PubMed ID: 12072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diet-induced improvement of abnormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus.
    Savage PJ; Bennion LJ; Flock EV; Nagulesparan M; Mott D; Roth J; Unger RH; Bennett PH
    J Clin Endocrinol Metab; 1979 Jun; 48(6):999-1007. PubMed ID: 447806
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of PGE2 on sulfonylurea induced insulin release.
    Villar A; Ivorra MD; Anselmi E
    J Physiol (Paris); 1987; 82(1):12-7. PubMed ID: 3123643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.